A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Phase 1 Not yet recruiting 130 enrolled 3H (Suzhou) Pharmaceuticals Co., Ltd.

Non-randomizedSequentialOpen-labelTreatment

Summary

The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations. Patients will be enrolled in two stages: dose escalation stage (Stage I) and expansion stage (Stage II).

Timeline

Start: 2026-06
Primary completion: 2028-03
Completion: 2028-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	3HP-2827	Unknown	—	Oral

Indications

No indication recorded.